Posted 7:11 am, Updated at 16:48
Here is a selection of the ads that have (or will) drive the prices of these companies:
(Come back and read us from time to time
So you never miss an update)
The dairy-free Scottish cheese maker and American factory specializing in value-added ingredients has moved into a multinational company a favour (Saab, $ 40.51). The total shopping bill is approximately $ 187 million. The dairy said Tuesday it has acquired Bute Island Foods and is on the verge of closing a deal for the Reedsburg specialty protein plant in Wisconsin. Saputo believes these acquisitions are in line with its global strategic plan, which it will unveil by the end of next week, along with its results at the end of the year. Bute Island Foods is a manufacturer and distributor of dairy-free cheeses for the retail and food service industries. It owns the “Sheese” brand for vegan products and its own brands. In a press release, Chairman and CEO, Lino Saputo, explained that he wants to expand Saputo’s presence “in the dairy substitute sector, in order to meet the changing requirements of our customers and consumers”.
American Investment Bank Goldman Sachs (GS, US $ 364.51) announced Tuesday that it has received initial mandate from Chinese authorities to set up a joint wealth management venture with one of the country’s largest financial institutions, the Industrial and Commercial Bank of China (ICBC). Goldman Sachs will own a 51% stake in the new company, which will combine its “expertise in investment and risk management” with “ICBC’s strong reputation and unparalleled reach to retail and institutional clients across China,” according to our correspondent. China’s financial markets are opening up more and more to foreign players, and the authorities of the country, the world’s second largest economy, have given them more freedom in their activities in recent years.
The British Competition Authority (CMA) on Tuesday launched a study on the acquisition of the US company Alexion (ALXN, $ 177.10) by the Swedish-British giant AstraZeneca (AZN, £ 8,083), $ 39 billion deal. In a press release, the Capital Markets Authority made it clear that it wanted to determine whether this deal could “lead to a significant reduction in competition” in the UK. She explained that she would call for public comments until June 3, without further details. It will announce whether it will launch an in-depth investigation in the second phase by July 21, and can then request “amendments to the proposed merger,” that is, divestment. Announced in December, the acquisition of the US biotechnology company that specializes in rare diseases, was announced by nearly unanimous shareholders.